Clinical observation of treating gastric cancer with peritoneal metastases: Pressurized intraperitoneal docetaxel administration

Peritoneal dissemination is one of the most frequent metastatic pattern of advanced gastric cancer. Currently, its prognosis remains poor. It is possible to improve treatment outcomes in a carefully selected group of patients through a combination of systemic and local therapies. This publication presents a clinical case of peritoneal disseminated gastric cancer treatment using a combination of systemic triple chemotherapy and pressurized intraperitoneal aerosol chemotherapy with docetaxel. Objective. The aim of the article is to study the treatment outcomes for metastatic gastric cancer with peritoneal dissemination using pressurized intraperitoneal docetaxel injection (clinical case study). Materials and Methods. We assessed the tolerability, efficacy, and safety of the treatment method used, the pathological response of peritoneal lesions, the primary tumor, and quality of life during treatment and the follow-up period. The example was a clinical case of stage IV gastric cancer treatment, cT4aN1M1 (Cy+, per+ PCI 5) using the FLOT regimen (3 cycles) + (mFLOT (3 cycles) + dPIPAC) regimen. Results. The study demonstrates successful application of docetaxel via pressurized intraperitoneal aerosol administration as part of systemic treatment in first-line chemotherapy. After achieving complete pathomorphological regression of gastric cancer peritoneal metastases using systemic chemotherapy and pressurized intraperitoneal chemotherapy, surgical treatment resulted in no surgical complications or deterioration in quality of life during a 1-year follow-up period Conclusion. Given the limited treatment options for patients with gastric cancer and peritoneal dissemination, the proposed method may become a viable therapeutic option.